product name Levetiracetam
Description: Levetiracetam (also known as UCB-L059, SIB-S1) is an anticonvulsant medication used to treat epilepsy. Levetiracetam and related compounds bind to SV2A expressed in fibroblasts, indicating that SV2A is sufficient for Levetiracetam binding. Levetiracetam irreversibly inhibits the high-voltage-activated (HVA) calcium current by approximately 18% on the average in freshly isolated CA1 hippocampal neurons of rats. Levetiracetam selectively inhibits N-type Ca2+ channels of CA1 pyramidal hippocampal neurons.
References: Nature. 2005 May 26;435(7041):519-22; Br J Pharmacol. 2002 Jul;136(5):659-72.
170.21
Formula
C8H14N2O2
CAS No.
102767-28-2
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 34 mg/mL (199.8 mM)
Water: 34 mg/mL (199.8 mM)
Ethanol: 34 mg/mL (199.8 mM)
Solubility (In vivo)
Saline: 30 mg/mL
Synonyms
UCB-L059, SIB-S1
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/1940342
| In Vitro |
In vitro activity: Levetiracetam and related compounds bind to SV2A expressed in fibroblasts, indicating that SV2A is sufficient for Levetiracetam binding. Levetiracetam irreversibly inhibits the high-voltage-activated (HVA) calcium current by approximately 18% on the average in freshly isolated CA1 hippocampal neurons of rats. Levetiracetam selectively inhibits N-type Ca2+ channels of CA1 pyramidal hippocampal neurons. Levetiracetam reverses the inhibitory effect of DMCM on GABA-elicited currents in hippocampal neurons Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Levetiracetam (17 mg/kg) produces a potent suppression of sound-induced clonic convulsions in mice, and this protective effect is significantly abolished by co-administration of the beta-carboline FG 7142. Levetiracetam exerts potent anticonvulsant activity against both focal and secondarily generalized seizures in fully amygdala-kindled rats, i.e. , a model of temporal lobe epilepsy. Levetiracetam (13 mg/kg, 27 mg/kg or 54 mg/kg, i.p.) dose-dependently suppresses the increase in seizure severity and duration induced by repeated amygdala stimulation. Levetiracetam has a relatively short half-life (about 2-3 hours) in rats. Levetiracetam (5.4 mg/kg to 96 mg/kg i.p.) dose-dependently inhibits both wild running and tonic-clonic convulsions in the audiogenic-seizure prone rat. Levetiracetam markedly suppresses spontaneous spike-and-wave discharge (SWD) but leaves the underlying EEG trace normal in the GAERS model of petit mal epilepsy. |
| Animal model | |
| Formulation & Dosage | |
| References | Nature. 2005 May 26;435(7041):519-22; Br J Pharmacol. 2002 Jul;136(5):659-72. |
Related Posts
product name Levetiracetam
Description: Levetiracetam (also known as UCB-L059, SIB-S1) is an anticonvulsant medication used to treat epilepsy. Levetiracetam and related compounds bind to SV2A expressed in fibroblasts, indicating that SV2A is sufficient for Levetiracetam binding. Levetiracetam irreversibly inhibits the high-voltage-activated (HVA) calcium current by approximately 18% on the average in freshly isolated CA1 hippocampal neurons of rats. Levetiracetam selectively inhibits N-type Ca2+ channels of CA1 pyramidal hippocampal neurons.
References: Nature. 2005 May 26;435(7041):519-22; Br J Pharmacol. 2002 Jul;136(5):659-72.
170.21
Formula
C8H14N2O2
CAS No.
102767-28-2
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 34 mg/mL (199.8 mM)
Water: 34 mg/mL (199.8 mM)
Ethanol: 34 mg/mL (199.8 mM)
Solubility (In vivo)
Saline: 30 mg/mL
Synonyms
UCB-L059, SIB-S1
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/1940342
| In Vitro |
In vitro activity: Levetiracetam and related compounds bind to SV2A expressed in fibroblasts, indicating that SV2A is sufficient for Levetiracetam binding. Levetiracetam irreversibly inhibits the high-voltage-activated (HVA) calcium current by approximately 18% on the average in freshly isolated CA1 hippocampal neurons of rats. Levetiracetam selectively inhibits N-type Ca2+ channels of CA1 pyramidal hippocampal neurons. Levetiracetam reverses the inhibitory effect of DMCM on GABA-elicited currents in hippocampal neurons Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Levetiracetam (17 mg/kg) produces a potent suppression of sound-induced clonic convulsions in mice, and this protective effect is significantly abolished by co-administration of the beta-carboline FG 7142. Levetiracetam exerts potent anticonvulsant activity against both focal and secondarily generalized seizures in fully amygdala-kindled rats, i.e. , a model of temporal lobe epilepsy. Levetiracetam (13 mg/kg, 27 mg/kg or 54 mg/kg, i.p.) dose-dependently suppresses the increase in seizure severity and duration induced by repeated amygdala stimulation. Levetiracetam has a relatively short half-life (about 2-3 hours) in rats. Levetiracetam (5.4 mg/kg to 96 mg/kg i.p.) dose-dependently inhibits both wild running and tonic-clonic convulsions in the audiogenic-seizure prone rat. Levetiracetam markedly suppresses spontaneous spike-and-wave discharge (SWD) but leaves the underlying EEG trace normal in the GAERS model of petit mal epilepsy. |
| Animal model | |
| Formulation & Dosage | |
| References | Nature. 2005 May 26;435(7041):519-22; Br J Pharmacol. 2002 Jul;136(5):659-72. |